Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00649077 · ClinicalTrials.gov registry record · Phase 1
Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00649077 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT00649077, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The objective of this study was to investigate the bioequivalence of Mylan's meloxicam 15 mg tablets and Boehringer Ingelheim's Mobic® 15 mg tablets following a single, oral 15 mg (1 x 15 mg) dose administration under fasting conditions.
Interventions
- DRUG Meloxicam Tablets 15 mg
- DRUG Mobic® Tablets 15 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-08 |
| Est. Completion | 2004-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00649077
The ClinicalTrials.gov registry entry for NCT00649077 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Pharmaceuticals, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Meloxicam Tablets 15 mg is the first listed.
NCT00649077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00649077 about?
NCT00649077 is a clinical study titled "Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg". The objective of this study was to investigate the bioequivalence of Mylan's meloxicam 15 mg tablets and Boehringer Ingelheim's Mobic® 15 mg tablets following a single, oral 15 mg (1 x 15 mg) dose administration under fasting conditions.
What is the current status of trial NCT00649077?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2004-08. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00649077?
The interventions under investigation include: Meloxicam Tablets 15 mg (DRUG), Mobic® Tablets 15 mg (DRUG).
Who is sponsoring clinical trial NCT00649077?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.